Form 4: Maze Therapeutics Insider Buys Shares

Atul Dandekar, Chief Business Officer of Maze Therapeutics, acquired a significant number of company shares through stock options on May 4, 2026.

Summary

• Atul Dandekar, Chief Business Officer (CSBO) of Maze Therapeutics, Inc., reported transactions on May 4, 2026.
• Dandekar acquired 8,320 shares of common stock at a price of $10.42 per share, totaling $86,782.40.
• Additionally, he acquired another 5,985 shares of common stock at the same price of $10.42 per share, totaling $62,425.70.
• These acquisitions were made through the exercise of stock options.
• Following these transactions, Dandekar beneficially owns 18,823 shares directly and 24,808 shares directly, with a total of 43,631 shares after accounting for the exercised options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider purchases can be positive, this transaction is primarily an exercise of stock options, which is a routine part of executive compensation and does not inherently signal a significant change in the company's outlook.

Positives

• Insider purchase of company stock by a key executive (CSBO) can signal confidence in the company's future prospects.
• The acquisition of shares through stock options at a price of $10.42 suggests the current market price may be at or above this level, potentially indicating a stable or growing valuation.
• The reporting person has a significant number of shares beneficially owned, indicating a substantial personal investment in the company.

Negatives

• The filing only reports transactions and does not provide financial performance data or strategic updates, making it difficult to assess the overall health of the company.
• The acquisition is through stock options, which is a common form of executive compensation and may not solely represent a conviction in future stock appreciation beyond the option grant terms.

Risks

• The filing does not explicitly mention any risks or challenges.
• As a Form 4 filing, it is limited to reporting changes in beneficial ownership and does not contain forward-looking statements or risk factor disclosures.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly stock option exercises and subsequent share acquisitions, are common within the biotechnology and pharmaceutical sectors as a component of executive compensation and a signal of executive commitment.

Stakeholder Impact

• Shareholders: The purchase by a key executive may be interpreted as a positive signal of confidence, though the transaction is an exercise of options, which is a standard compensation mechanism.
• Employees: May view the executive's investment as a sign of stability and potential growth.
• Management: The transaction reflects the ongoing compensation structure for senior leadership.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Options, Beneficial Ownership, Executive Compensation, Atul Dandekar, CSBO